# Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects

> **NCT01313962** · PHASE1 · COMPLETED · sponsor: **Autoimmune Technologies, LLC** · enrollment: 32 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Flufirvitide-3 0.05 mg single dose
- **DRUG:** Flufirvitide-3, 0.1 mg single dose
- **DRUG:** Flufirvitide-3, 0.2 mg single dose
- **DRUG:** Flufirvitide-3, 0.4 mg single dose
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01313962
- **Lead sponsor:** Autoimmune Technologies, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2012-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01313962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01313962, "Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01313962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*